Arsenic Exposure and Prevalence of the Varicella Zoster Virus in the United States: NHANES (2003-2004 and 2009-2010)

Overview

Journal Environ Health Perspect

Date 2015 Jan 31

PMID 25636148

Citations 21

Authors

Andres Cardenas

Ellen Smit

E Andres Houseman

Nancy I Kerkvliet

Jeffrey W Bethel

Molly L Kile

Affiliations

Soon will be listed here.

Abstract

Background: Arsenic is an immunotoxicant. Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovered from arsenic poisoning and in patients with acute promyelocytic leukemia that have been treated with arsenic trioxide.

Objective: We evaluated the association between arsenic and the seroprevalence of VZV IgG antibody in a representative sample of the U.S.

Methods: We analyzed data from 3,348 participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and 2009-2010 pooled survey cycles. Participants were eligible if they were 6-49 years of age with information on both VZV IgG and urinary arsenic concentrations. We used two measures of total urinary arsenic (TUA): TUA1 was defined as the sum of arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, and TUA2 was defined as total urinary arsenic minus arsenobetaine and arsenocholine.

Results: The overall weighted seronegative prevalence of VZV was 2.2% for the pooled NHANES sample. The geometric means of TUA1 and TUA2 were 6.57 μg/L and 5.64 μg/L, respectively. After adjusting for age, sex, race, income, creatinine, and survey cycle, odds ratios for a negative VZV IgG result in association with 1-unit increases in natural log-transformed (ln)-TUA1 and ln-TUA2 were 1.87 (95% CI: 1.03, 3.44) and 1.40 (95% CI: 1.0, 1.97), respectively.

Conclusions: In this cross-sectional analysis, urinary arsenic was inversely associated with VZV IgG seroprevalence in the U.S.

Population: This finding is in accordance with clinical observations of zoster virus reactivation from high doses of arsenic. Additional studies are needed to confirm the association and evaluate causal mechanisms.

Citing Articles

Rare Earth and Platinum Group Elements In Sub-Saharan Africa and Global Health: The Dark Side of the Burgeoning of Technology.

Frazzoli C, Bocca B, Battistini B, Ruggieri F, Rovira J, Amadi C Environ Health Insights. 2024; 18:11786302241271553.

PMID: 39282214 PMC: 11393805. DOI: 10.1177/11786302241271553.

Continuing the Conversation About Arsenic.

Pizzorno J Integr Med (Encinitas). 2024; 23(3):6-10.

PMID: 39114283 PMC: 11302974.

Time to Recognize and Address the Serious Arsenic Problem.

Pizzorno J Integr Med (Encinitas). 2024; 23(1):6-9.

PMID: 38618164 PMC: 11007617.

Update of the risk assessment of inorganic arsenic in food.

Schrenk D, Bignami M, Bodin L, Chipman J, Del Mazo J, Grasl-Kraupp B EFSA J. 2024; 22(1):e8488.

PMID: 38239496 PMC: 10794945. DOI: 10.2903/j.efsa.2024.8488.

The interplay between environmental exposures and COVID-19 risks in the health of children.

Sly P, Trottier B, Bulka C, Cormier S, Fobil J, Fry R Environ Health. 2021; 20(1):34.

PMID: 33771185 PMC: 7996114. DOI: 10.1186/s12940-021-00716-z.

References

Lemarie A, Morzadec C, Merino D, Micheau O, Fardel O, Vernhet L . Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation. J Pharmacol Exp Ther. 2005; 316(1):304-14. DOI: 10.1124/jpet.105.092874. View

Soto-Pena G, Luna A, Acosta-Saavedra L, Conde P, Lopez-Carrillo L, Cebrian M . Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J. 2006; 20(6):779-81. DOI: 10.1096/fj.05-4860fje. View

Kozul C, Hampton T, Davey J, Gosse J, Nomikos A, Eisenhauer P . Chronic exposure to arsenic in the drinking water alters the expression of immune response genes in mouse lung. Environ Health Perspect. 2009; 117(7):1108-15. PMC: 2717138. DOI: 10.1289/ehp.0800199. View

Tanvetyanon T, Nand S . Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004; 83(3):198-200. DOI: 10.1007/s00277-003-0749-3. View

Nouri K, Ricotti Jr C, Bouzari N, Chen H, Ahn E, Bach A . The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J Drugs Dermatol. 2006; 5(2):182-5. View

Au W, Kwong Y . Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol. 2005; 53(5):890-2. DOI: 10.1016/j.jaad.2005.07.030. View

Barr D, Wilder L, Caudill S, Gonzalez A, Needham L, Pirkle J . Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005; 113(2):192-200. PMC: 1277864. DOI: 10.1289/ehp.7337. View

Burns L, MUNSON A . Gallium arsenide selectively inhibits T cell proliferation and alters expression of CD25 (IL-2R/p55). J Pharmacol Exp Ther. 1993; 265(1):178-86. View

Hope-Simpson R . THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med. 1965; 58:9-20. PMC: 1898279. View

10.

Hammond O, Wang Y, Green T, Antonello J, Kuhn R, Motley C . The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol. 2006; 78(12):1679-87. DOI: 10.1002/jmv.20754. View

11.

Murer A, Abildtrup A, Poulsen O, Christensen J . Effect of seafood consumption on the urinary level of total hydride-generating arsenic compounds. Instability of arsenobetaine and arsenocholine. Analyst. 1992; 117(3):677-80. DOI: 10.1039/an9921700677. View

12.

Sikorski E, McCay J, White Jr K, BRADLEY S, MUNSON A . Immunotoxicity of the semiconductor gallium arsenide in female B6C3F1 mice. Fundam Appl Toxicol. 1989; 13(4):843-58. DOI: 10.1016/0272-0590(89)90338-2. View

13.

Forghani B, SCHMIDT N, Dennis J . Antibody assays for varicella-zoster virus: comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation. J Clin Microbiol. 1978; 8(5):545-52. PMC: 275295. DOI: 10.1128/jcm.8.5.545-552.1978. View

14.

Marin M, Guris D, Chaves S, Schmid S, Seward J . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-4):1-40. View

15.

Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A . A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia. 2004; 18(9):1518-21. DOI: 10.1038/sj.leu.2403424. View

16.

Bourdonnay E, Morzadec C, Sparfel L, Galibert M, Jouneau S, Martin-Chouly C . Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009; 46(4):649-56. DOI: 10.1016/j.molimm.2008.08.268. View

17.

Carlill H . A NOTE ON THE ASSOCIATION OF HERPES ZOSTER WITH ARSENIC. Br Med J. 2010; 2(2949):9. PMC: 2355185. DOI: 10.1136/bmj.2.2949.9. View

18.

Davis M, MacKenzie T, Cottingham K, Gilbert-Diamond D, Punshon T, Karagas M . Rice consumption and urinary arsenic concentrations in U.S. children. Environ Health Perspect. 2012; 120(10):1418-24. PMC: 3491944. DOI: 10.1289/ehp.1205014. View

19.

Yoshida T, Shimamura T, Shigeta S . Enhancement of the immune response in vitro by arsenic. Int J Immunopharmacol. 1987; 9(3):411-5. DOI: 10.1016/0192-0561(87)90068-3. View

20.

Reynolds M, Kruszon-Moran D, Jumaan A, Schmid D, McQuillan G . Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999-2004. Public Health Rep. 2010; 125(6):860-9. PMC: 2966667. DOI: 10.1177/003335491012500613. View